To Amend The Composition Of The Arkansas Medicaid Drug Utilization Review Board To Include Physician Assistants.
Summary
SB187 amends Arkansas law governing the composition of the Medicaid Drug Utilization Review Board. Under current law, the appointed clinical members are physicians; the bill expands that eligibility so the board may include physicians, physician assistants, or advanced practice registered nurses. The other qualifications remain the same: appointees must be licensed and practicing in Arkansas and must currently treat rare diseases or conditions.
The practical effect of the bill is to broaden the pool of health professionals who can serve on the board that reviews Medicaid drug use and utilization issues. By adding physician assistants and APRNs, the bill gives the state more flexibility in filling board seats and may increase representation from providers who actively participate in patient care, especially in specialty and rare-disease treatment settings. The bill does not change Medicaid benefits or drug coverage rules directly, but it does affect the advisory and review body that helps oversee those policies.
Impact
SB187 amends Arkansas Code § 20-77-143(c)(2) to change who may be appointed to the Arkansas Medicaid Drug Utilization Review Board. It expands the statutory membership criteria from physicians only to physicians, physician assistants, or advanced practice registered nurses, while preserving the requirements that members be licensed, practicing in Arkansas, and currently treating rare diseases or conditions. The bill therefore affects state Medicaid governance and board composition rather than substantive eligibility or reimbursement statutes.
Sentiment
The available voting history suggests strong support for the bill. It passed third reading in the Senate by a 32-0 vote, indicating unanimous approval among those voting. No committee transcript is available, but the vote total and lack of recorded opposition point to a broadly favorable view of the measure.
Contention
No major contention is evident in the available record. The only potential policy issue is whether board seats should remain limited to physicians or be opened to physician assistants and advanced practice registered nurses. Supporters likely view the change as a practical modernization that expands the pool of qualified clinicians, while any concern would center on preserving physician-led oversight of Medicaid drug utilization review. However, the unanimous vote suggests little to no active opposition.